2 results
Approved WMOCompleted
Primary: To demonstrate the efficacy of each secukinumab regimen at Week 16 is superior to placebo in patients with active AS based on the proportion of patients achieving an ASAS 20 response in the subgroup of patients who are TNFα inhibitor naïve.…
Approved WMOCompleted
To determine the pharmacokinetic properties of a new elacridar formulation